Co-Authors
This is a "connection" page, showing publications co-authored by VIVEK SUBBIAH and MOUHAMMED A HABRA.
Connection Strength
0.418
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.188
-
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253.
Score: 0.182
-
Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel). 2020 Aug 16; 12(8).
Score: 0.048